JP2010540593A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010540593A5 JP2010540593A5 JP2010527450A JP2010527450A JP2010540593A5 JP 2010540593 A5 JP2010540593 A5 JP 2010540593A5 JP 2010527450 A JP2010527450 A JP 2010527450A JP 2010527450 A JP2010527450 A JP 2010527450A JP 2010540593 A5 JP2010540593 A5 JP 2010540593A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- asthma
- dermatitis
- syndrome
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 tautomers Substances 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 9
- 239000011780 sodium chloride Substances 0.000 claims 9
- 208000006673 Asthma Diseases 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 8
- 201000004624 dermatitis Diseases 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 6
- 239000012453 solvate Substances 0.000 claims 6
- 231100000406 dermatitis Toxicity 0.000 claims 5
- 230000000302 ischemic Effects 0.000 claims 5
- 229940079593 drugs Drugs 0.000 claims 4
- 238000002054 transplantation Methods 0.000 claims 4
- 206010003210 Arteriosclerosis Diseases 0.000 claims 3
- 206010003816 Autoimmune disease Diseases 0.000 claims 3
- 208000000594 Bullous Pemphigoid Diseases 0.000 claims 3
- 206010018364 Glomerulonephritis Diseases 0.000 claims 3
- 206010019663 Hepatic failure Diseases 0.000 claims 3
- 208000007903 Liver Failure Diseases 0.000 claims 3
- 206010034277 Pemphigoid Diseases 0.000 claims 3
- 206010046851 Uveitis Diseases 0.000 claims 3
- 230000001684 chronic Effects 0.000 claims 3
- 231100000835 liver failure Toxicity 0.000 claims 3
- 210000000056 organs Anatomy 0.000 claims 3
- 229920000728 polyester Polymers 0.000 claims 3
- 201000000306 sarcoidosis Diseases 0.000 claims 3
- 208000009137 Behcet Syndrome Diseases 0.000 claims 2
- 201000008335 Behcet's disease Diseases 0.000 claims 2
- 206010012601 Diabetes mellitus Diseases 0.000 claims 2
- 208000005679 Eczema Diseases 0.000 claims 2
- 206010015150 Erythema Diseases 0.000 claims 2
- 206010018651 Graft versus host disease Diseases 0.000 claims 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 2
- 208000003084 Graves Ophthalmopathy Diseases 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 206010021198 Ichthyosis Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 206010021972 Inflammatory bowel disease Diseases 0.000 claims 2
- 206010023332 Keratitis Diseases 0.000 claims 2
- 206010036105 Polyneuropathy Diseases 0.000 claims 2
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 2
- 206010047642 Vitiligo Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 201000005794 allergic hypersensitivity disease Diseases 0.000 claims 2
- 201000004384 alopecia Diseases 0.000 claims 2
- 231100000360 alopecia Toxicity 0.000 claims 2
- 230000003698 anagen phase Effects 0.000 claims 2
- 230000001363 autoimmune Effects 0.000 claims 2
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 claims 2
- 239000002585 base Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 231100001003 eczema Toxicity 0.000 claims 2
- 231100000321 erythema Toxicity 0.000 claims 2
- 230000003779 hair growth Effects 0.000 claims 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims 2
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 2
- 230000009610 hypersensitivity Effects 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 201000002674 obstructive nephropathy Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 201000004681 psoriasis Diseases 0.000 claims 2
- 201000010874 syndrome Diseases 0.000 claims 2
- 206010000496 Acne Diseases 0.000 claims 1
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 claims 1
- 208000007788 Acute Liver Failure Diseases 0.000 claims 1
- 201000004304 Addison's disease Diseases 0.000 claims 1
- 206010064930 Age-related macular degeneration Diseases 0.000 claims 1
- 208000010002 Alcoholic Liver Cirrhosis Diseases 0.000 claims 1
- 208000004631 Alopecia Areata Diseases 0.000 claims 1
- 208000008445 Altitude Sickness Diseases 0.000 claims 1
- 206010001897 Alzheimer's disease Diseases 0.000 claims 1
- 108009000433 Amyotrophic lateral sclerosis (ALS) Proteins 0.000 claims 1
- 206010002065 Anaemia megaloblastic Diseases 0.000 claims 1
- 208000009094 Anemia, Hemolytic, Autoimmune Diseases 0.000 claims 1
- 206010002425 Angioedemas Diseases 0.000 claims 1
- 208000008637 Anti-Glomerular Basement Membrane Disease Diseases 0.000 claims 1
- 206010002967 Aplastic anaemia Diseases 0.000 claims 1
- 206010003645 Atopy Diseases 0.000 claims 1
- 208000005783 Autoimmune Thyroiditis Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 206010060945 Bacterial infection Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 206010004659 Biliary cirrhosis Diseases 0.000 claims 1
- 206010004661 Biliary cirrhosis primary Diseases 0.000 claims 1
- 210000004204 Blood Vessels Anatomy 0.000 claims 1
- 210000001185 Bone Marrow Anatomy 0.000 claims 1
- 210000000988 Bone and Bones Anatomy 0.000 claims 1
- 210000004556 Brain Anatomy 0.000 claims 1
- 208000008581 Brain Disease Diseases 0.000 claims 1
- 206010006451 Bronchitis Diseases 0.000 claims 1
- 208000005623 Carcinogenesis Diseases 0.000 claims 1
- 208000005846 Cardiomyopathy Diseases 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 1
- 208000002691 Choroiditis Diseases 0.000 claims 1
- 208000009863 Chronic Kidney Failure Diseases 0.000 claims 1
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 claims 1
- 206010009208 Cirrhosis alcoholic Diseases 0.000 claims 1
- 206010009657 Clostridium difficile colitis Diseases 0.000 claims 1
- 206010009839 Coeliac disease Diseases 0.000 claims 1
- 206010009887 Colitis Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000010247 Contact Dermatitis Diseases 0.000 claims 1
- 206010011401 Crohn's disease Diseases 0.000 claims 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 claims 1
- 210000001750 Dental Cementum Anatomy 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathy Diseases 0.000 claims 1
- 206010061835 Diabetic nephropathy Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 206010014623 Encephalopathy Diseases 0.000 claims 1
- 206010014625 Encephalopathy Diseases 0.000 claims 1
- 206010014824 Endotoxic shock Diseases 0.000 claims 1
- 206010014954 Eosinophilic fasciitis Diseases 0.000 claims 1
- 206010014989 Epidermolysis bullosa Diseases 0.000 claims 1
- 210000003743 Erythrocytes Anatomy 0.000 claims 1
- 206010016717 Fistula Diseases 0.000 claims 1
- 210000004195 Gingiva Anatomy 0.000 claims 1
- 208000007565 Gingivitis Diseases 0.000 claims 1
- 206010018620 Goodpasture's syndrome Diseases 0.000 claims 1
- 206010018687 Granulocytopenia Diseases 0.000 claims 1
- 208000002183 Guillain-Barre Syndrome Diseases 0.000 claims 1
- 206010019692 Hepatic necrosis Diseases 0.000 claims 1
- 208000006454 Hepatitis Diseases 0.000 claims 1
- 208000002672 Hepatitis B Diseases 0.000 claims 1
- 206010019799 Hepatitis viral Diseases 0.000 claims 1
- 208000005100 Herpetic Keratitis Diseases 0.000 claims 1
- 206010020850 Hyperthyroidism Diseases 0.000 claims 1
- 206010021074 Hypoplastic anaemia Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 206010021197 Ichthyosis Diseases 0.000 claims 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
- 206010022114 Injury Diseases 0.000 claims 1
- 206010061255 Ischaemia Diseases 0.000 claims 1
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025135 Lupus erythematosus Diseases 0.000 claims 1
- 208000003543 Lymphoma, T-Cell, Cutaneous Diseases 0.000 claims 1
- 208000009029 Macular Degeneration, Age-Related, 2 Diseases 0.000 claims 1
- 208000008585 Mastocytosis Diseases 0.000 claims 1
- 208000000682 Megaloblastic Anemia Diseases 0.000 claims 1
- 206010027183 Meniere's disease Diseases 0.000 claims 1
- 206010027476 Metastasis Diseases 0.000 claims 1
- 206010027599 Migraine Diseases 0.000 claims 1
- 208000008085 Migraine Disorders Diseases 0.000 claims 1
- 206010027910 Mononeuritis Diseases 0.000 claims 1
- 201000009262 Mooren's ulcer Diseases 0.000 claims 1
- 208000003627 Muscular Dystrophy Diseases 0.000 claims 1
- 206010028417 Myasthenia gravis Diseases 0.000 claims 1
- 208000003926 Myelitis Diseases 0.000 claims 1
- 206010073938 Ophthalmic herpes simplex Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 210000002379 Periodontal Ligament Anatomy 0.000 claims 1
- 206010034695 Pernicious anaemia Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 208000005374 Poisoning Diseases 0.000 claims 1
- 208000005987 Polymyositis Diseases 0.000 claims 1
- 208000003971 Posterior Uveitis Diseases 0.000 claims 1
- 206010036774 Proctitis Diseases 0.000 claims 1
- 206010037128 Pseudomembranous colitis Diseases 0.000 claims 1
- 208000005069 Pulmonary Fibrosis Diseases 0.000 claims 1
- 208000002098 Purpura, Thrombocytopenic, Idiopathic Diseases 0.000 claims 1
- 208000006311 Pyoderma Diseases 0.000 claims 1
- 206010037779 Radiculopathy Diseases 0.000 claims 1
- 206010038436 Renal failure acute Diseases 0.000 claims 1
- 206010038444 Renal failure chronic Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000007014 Retinitis Pigmentosa Diseases 0.000 claims 1
- 206010039083 Rhinitis Diseases 0.000 claims 1
- 208000003385 Rhinitis, Allergic, Seasonal Diseases 0.000 claims 1
- 210000003786 Sclera Anatomy 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000010157 Sclerosing Cholangitis Diseases 0.000 claims 1
- 208000008742 Seborrheic Dermatitis Diseases 0.000 claims 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 206010040767 Sjogren's syndrome Diseases 0.000 claims 1
- 210000003491 Skin Anatomy 0.000 claims 1
- 208000006641 Skin Disease Diseases 0.000 claims 1
- 208000007107 Stomach Ulcer Diseases 0.000 claims 1
- 208000001106 Takayasu Arteritis Diseases 0.000 claims 1
- 231100000765 Toxin Toxicity 0.000 claims 1
- 206010064996 Ulcerative keratitis Diseases 0.000 claims 1
- 206010046736 Urticarias Diseases 0.000 claims 1
- 208000001445 Uveomeningoencephalitic Syndrome Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 206010047680 Vogt-Koyanagi-Harada syndrome Diseases 0.000 claims 1
- 230000001154 acute Effects 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000000240 adjuvant Effects 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 201000010000 agranulocytosis Diseases 0.000 claims 1
- 239000003513 alkali Substances 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 230000000172 allergic Effects 0.000 claims 1
- 201000009961 allergic asthma Diseases 0.000 claims 1
- 125000004429 atoms Chemical group 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000036952 cancer formation Effects 0.000 claims 1
- 125000004432 carbon atoms Chemical group C* 0.000 claims 1
- 231100000504 carcinogenesis Toxicity 0.000 claims 1
- 201000009030 carcinoma Diseases 0.000 claims 1
- 201000008031 cardiomyopathy Diseases 0.000 claims 1
- 230000022534 cell killing Effects 0.000 claims 1
- 239000004568 cement Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 1
- 230000009089 cytolysis Effects 0.000 claims 1
- 231100000080 dermatitis contact Toxicity 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 230000018109 developmental process Effects 0.000 claims 1
- 201000009910 diseases by infectious agent Diseases 0.000 claims 1
- 239000000428 dust Substances 0.000 claims 1
- 238000003912 environmental pollution Methods 0.000 claims 1
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 claims 1
- 230000003890 fistula Effects 0.000 claims 1
- 238000005755 formation reaction Methods 0.000 claims 1
- 201000005917 gastric ulcer Diseases 0.000 claims 1
- 201000001066 hemolytic-uremic syndrome Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 229960001340 histamine Drugs 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 230000000521 hyperimmunizing Effects 0.000 claims 1
- 230000003463 hyperproliferative Effects 0.000 claims 1
- 230000001146 hypoxic Effects 0.000 claims 1
- 201000002597 ichthyosis vulgaris Diseases 0.000 claims 1
- 230000004957 immunoregulator effect Effects 0.000 claims 1
- 230000002757 inflammatory Effects 0.000 claims 1
- 200000000018 inflammatory disease Diseases 0.000 claims 1
- 201000006334 interstitial nephritis Diseases 0.000 claims 1
- 230000003903 intestinal lesions Effects 0.000 claims 1
- 201000010659 intrinsic asthma Diseases 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 201000010666 keratoconjunctivitis Diseases 0.000 claims 1
- 201000002287 keratoconus Diseases 0.000 claims 1
- 210000002429 large intestine Anatomy 0.000 claims 1
- 230000003902 lesions Effects 0.000 claims 1
- GWNVDXQDILPJIG-NXOLIXFESA-N leukotriene C4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O GWNVDXQDILPJIG-NXOLIXFESA-N 0.000 claims 1
- 201000011486 lichen planus Diseases 0.000 claims 1
- 201000004044 liver cirrhosis Diseases 0.000 claims 1
- 231100000149 liver necrosis Toxicity 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 231100001016 megaloblastic anemia Toxicity 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000006938 muscular dystrophy Diseases 0.000 claims 1
- 201000005962 mycosis fungoide Diseases 0.000 claims 1
- 201000002481 myositis Diseases 0.000 claims 1
- 201000009240 nasopharyngitis Diseases 0.000 claims 1
- 230000001338 necrotic Effects 0.000 claims 1
- 230000017074 necrotic cell death Effects 0.000 claims 1
- 230000000414 obstructive Effects 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 201000008838 periodontal disease Diseases 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000000607 poisoning Effects 0.000 claims 1
- 231100000572 poisoning Toxicity 0.000 claims 1
- 201000006292 polyarteritis nodosa Diseases 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 238000004321 preservation Methods 0.000 claims 1
- 230000003658 preventing hair loss Effects 0.000 claims 1
- 201000002728 primary biliary cirrhosis Diseases 0.000 claims 1
- 230000001737 promoting Effects 0.000 claims 1
- 230000002685 pulmonary Effects 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 230000002441 reversible Effects 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 230000037390 scarring Effects 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 230000001225 therapeutic Effects 0.000 claims 1
- 210000001519 tissues Anatomy 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 201000006704 ulcerative colitis Diseases 0.000 claims 1
- 201000001862 viral hepatitis Diseases 0.000 claims 1
- XOFLBQFBSOEHOG-UUOKFMHZSA-N γS-GTP Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=S)[C@@H](O)[C@H]1O XOFLBQFBSOEHOG-UUOKFMHZSA-N 0.000 claims 1
- 0 Cc1ccccc1-c(cc1)c([C@@](*=O)[O-])cc1C1=NC(c(cccc2)c2OC)=*=CO1 Chemical compound Cc1ccccc1-c(cc1)c([C@@](*=O)[O-])cc1C1=NC(c(cccc2)c2OC)=*=CO1 0.000 description 11
- ZECNIOSRNLMLQL-UHFFFAOYSA-N CC(C(C=C1C2=[I]COC(c(cc3C)cnc3N3C(COC)CCC3)=N2)=CCC1OC)=C Chemical compound CC(C(C=C1C2=[I]COC(c(cc3C)cnc3N3C(COC)CCC3)=N2)=CCC1OC)=C ZECNIOSRNLMLQL-UHFFFAOYSA-N 0.000 description 1
- LMEIQOZLQFASPG-UHFFFAOYSA-N CC(C)Cc(cc1)ccc1C1=NC(c2ccccc2OC)=CCO1 Chemical compound CC(C)Cc(cc1)ccc1C1=NC(c2ccccc2OC)=CCO1 LMEIQOZLQFASPG-UHFFFAOYSA-N 0.000 description 1
- FJCWNYMWFMXWIG-UHFFFAOYSA-N CC(C1)C(OC)=CC(OC)=C1c(cc1)c(C)cc1-c1nc(-c(cccc2)c2OC)n[o]1 Chemical compound CC(C1)C(OC)=CC(OC)=C1c(cc1)c(C)cc1-c1nc(-c(cccc2)c2OC)n[o]1 FJCWNYMWFMXWIG-UHFFFAOYSA-N 0.000 description 1
- RDZNOCMUKDFOEB-UHFFFAOYSA-N CC(CCCC1)N1C(C=C1)=NCC=C1c1nc(-c(cc(cc2)F)c2OC)n[o]1 Chemical compound CC(CCCC1)N1C(C=C1)=NCC=C1c1nc(-c(cc(cc2)F)c2OC)n[o]1 RDZNOCMUKDFOEB-UHFFFAOYSA-N 0.000 description 1
- HBZMDATWKNBZOL-UHFFFAOYSA-N CN(CCOC1)C1I Chemical compound CN(CCOC1)C1I HBZMDATWKNBZOL-UHFFFAOYSA-N 0.000 description 1
- PAMIQIKDUOTOBW-UHFFFAOYSA-N CN1CCCCC1 Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 1
- GJSVCUHWEJFFMO-UHFFFAOYSA-N Cc(nccc1)c1I Chemical compound Cc(nccc1)c1I GJSVCUHWEJFFMO-UHFFFAOYSA-N 0.000 description 1
- YFSLWFVIZJXFTH-UHFFFAOYSA-N Cc1c(C)[o]nc1I Chemical compound Cc1c(C)[o]nc1I YFSLWFVIZJXFTH-UHFFFAOYSA-N 0.000 description 1
- MGGZZJQVRZTTSN-UHFFFAOYSA-N Cc1cc(-c2nc(-c(cccc3)c3OC(F)(F)F)n[o]2)ccc1-c1ccccc1OC Chemical compound Cc1cc(-c2nc(-c(cccc3)c3OC(F)(F)F)n[o]2)ccc1-c1ccccc1OC MGGZZJQVRZTTSN-UHFFFAOYSA-N 0.000 description 1
- XQPLNMPHXAMKKR-UHFFFAOYSA-N Cc1cc(-c2nc(-c(cccc3)c3OC)n[o]2)ccc1C1=CCCC=C1C Chemical compound Cc1cc(-c2nc(-c(cccc3)c3OC)n[o]2)ccc1C1=CCCC=C1C XQPLNMPHXAMKKR-UHFFFAOYSA-N 0.000 description 1
- FWIGHXDJQOUOMF-UHFFFAOYSA-N Cc1ccccc1-c(cc1)c(CN(C)C)cc1-c1nc(-c(cc(C=C)cc2)c2OC)n[o]1 Chemical compound Cc1ccccc1-c(cc1)c(CN(C)C)cc1-c1nc(-c(cc(C=C)cc2)c2OC)n[o]1 FWIGHXDJQOUOMF-UHFFFAOYSA-N 0.000 description 1
- PWMQGDXVGSGAHB-UHFFFAOYSA-N Cc1ccccc1-c(cc1)c(CN)cc1-c1nc(-c2cc(F)ccc2OC)n[o]1 Chemical compound Cc1ccccc1-c(cc1)c(CN)cc1-c1nc(-c2cc(F)ccc2OC)n[o]1 PWMQGDXVGSGAHB-UHFFFAOYSA-N 0.000 description 1
- MFQWILMXHRCFDY-UHFFFAOYSA-N Cc1ccccc1-c(ccc(-c1nc(-c2cc(F)ccc2OC)n[o]1)c1)c1C(O)=O Chemical compound Cc1ccccc1-c(ccc(-c1nc(-c2cc(F)ccc2OC)n[o]1)c1)c1C(O)=O MFQWILMXHRCFDY-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07117925 | 2007-10-04 | ||
| EP07117925.3 | 2007-10-04 | ||
| US99813607P | 2007-10-09 | 2007-10-09 | |
| US60/998,136 | 2007-10-09 | ||
| PCT/EP2008/063185 WO2009043890A1 (en) | 2007-10-04 | 2008-10-01 | Oxadiazole diaryl compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014197234A Division JP2015025001A (ja) | 2007-10-04 | 2014-09-26 | オキサジアゾール・ジアリール化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010540593A JP2010540593A (ja) | 2010-12-24 |
| JP2010540593A5 true JP2010540593A5 (US20070167479A1-20070719-C00034.png) | 2013-10-24 |
| JP5727223B2 JP5727223B2 (ja) | 2015-06-03 |
Family
ID=38961274
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010527450A Expired - Fee Related JP5727223B2 (ja) | 2007-10-04 | 2008-10-01 | オキサジアゾール・ジアリール化合物 |
| JP2014197234A Withdrawn JP2015025001A (ja) | 2007-10-04 | 2014-09-26 | オキサジアゾール・ジアリール化合物 |
| JP2016100693A Expired - Fee Related JP6224771B2 (ja) | 2007-10-04 | 2016-05-19 | オキサジアゾール・ジアリール化合物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014197234A Withdrawn JP2015025001A (ja) | 2007-10-04 | 2014-09-26 | オキサジアゾール・ジアリール化合物 |
| JP2016100693A Expired - Fee Related JP6224771B2 (ja) | 2007-10-04 | 2016-05-19 | オキサジアゾール・ジアリール化合物 |
Country Status (15)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2125797T3 (da) | 2007-03-16 | 2014-02-10 | Actelion Pharmaceuticals Ltd | Aminopyridinderivater som s1p1/edg1-receptoragonister |
| CN104478821B (zh) * | 2007-10-04 | 2016-09-28 | 默克雪兰诺有限公司 | 噁二唑二芳基化合物 |
| EA201070422A1 (ru) | 2007-10-04 | 2010-12-30 | Мерк Сероно С.А. | Производные оксадиазола |
| US8551463B2 (en) | 2007-10-22 | 2013-10-08 | Living Proof, Inc. | Hair care compositions and methods of treating hair |
| EP2250165B1 (en) * | 2007-12-21 | 2018-07-25 | Merck Serono S.A. | Triazole oxadiazoles derivatives |
| JP5411877B2 (ja) * | 2008-03-06 | 2014-02-12 | アクテリオン ファーマシューティカルズ リミテッド | ピリジン化合物 |
| EP2262782B1 (en) | 2008-03-07 | 2012-07-04 | Actelion Pharmaceuticals Ltd. | Novel aminomethyl benzene derivatives |
| JP2012515788A (ja) | 2009-01-23 | 2012-07-12 | ブリストル−マイヤーズ スクイブ カンパニー | 自己免疫疾患および炎症性疾患の処置における、ｓ１ｐアゴニストとしての置換オキサジアゾール誘導体 |
| ES2405054T3 (es) | 2009-01-23 | 2013-05-30 | Bristol-Myers Squibb Company | Derivados de pirazol-1,2,4-oxadiazol como agonistas de esfingosina-1-fosfato |
| CN102361867A (zh) | 2009-01-23 | 2012-02-22 | 百时美施贵宝公司 | 在治疗自身免疫疾病和炎性疾病中作为s1p激动剂的取代的噁二唑衍生物 |
| RU2547098C2 (ru) | 2009-07-16 | 2015-04-10 | Актелион Фармасьютиклз Лтд | Производные пиридин-4-ила |
| US8399451B2 (en) | 2009-08-07 | 2013-03-19 | Bristol-Myers Squibb Company | Heterocyclic compounds |
| WO2011133734A1 (en) | 2010-04-23 | 2011-10-27 | Bristol-Myers Squibb Company | 4 - (5 - isoxazolyl or 5 - pyrrazolyl -1,2,4- oxadiazol - 3 - yl) -mandelic acid amides as sphingosin- 1 - phosphate 1 rreceptor agonists |
| CA2797668A1 (en) | 2010-04-27 | 2011-11-03 | Allergan, Inc. | 3-(4-((1h-imidazol-1-yl)methyl)phenyl)-5-aryl-1,2,4-oxadiazole derivatives as sphingosine-1 phosphate receptors modulators |
| CN103237795B (zh) * | 2010-09-24 | 2015-10-21 | 百时美施贵宝公司 | 经取代的噁二唑化合物及其作为s1p1激动剂的用途 |
| WO2012098505A1 (en) | 2011-01-19 | 2012-07-26 | Actelion Pharmaceuticals Ltd | 2-methoxy-pyridin-4-yl derivatives |
| US9073881B2 (en) * | 2011-09-23 | 2015-07-07 | Hoffmann-La Roche Inc. | Benzoic acid derivatives |
| HUE047646T2 (hu) | 2015-05-20 | 2020-05-28 | Idorsia Pharmaceuticals Ltd | Az (S)-3-{4-[5-(2-ciklopentil-6-metoxi-piridin-4-il)-[1,2,4]oxadiazol-3-il]-2-etil-6-metil-fenoxi} -propán-1,2-diol vegyület kristályformája |
| EP4240350A4 (en) * | 2020-11-09 | 2024-09-18 | Arena Pharm Inc | <SUP2/>? <SUB2/>?1?METHODS OF TREATING DISEASES ASSOCIATED WITH THE S1P RECEPTOR |
| EP4050002A1 (en) * | 2021-02-26 | 2022-08-31 | First Health Pharmaceuticals B.V. | Anti-proliferative agents |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH623971B5 (de) | 1976-06-04 | 1982-01-15 | Hoechst Ag | Verfahren zur herstellung neuer benzofuranderivate und deren verwendung als optische aufheller. |
| US4135910A (en) | 1977-05-12 | 1979-01-23 | Monsanto Company | Oxadiazol-3-yl-benzoates as plant growth regulants |
| DE4320801A1 (de) | 1993-06-23 | 1995-01-05 | Fahlberg List Pharma Gmbh | 2-Hydroxyphenylsubstituierte 1,2,4-Triazole und 1,2,4-Oxadiazole, ihre Verwendung als pharmazeutische Wirkstoffe und sie enthaltende Arzneimittel |
| DE19643037A1 (de) * | 1996-10-18 | 1998-04-23 | Boehringer Ingelheim Kg | Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel |
| AUPP999799A0 (en) | 1999-04-27 | 1999-05-20 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
| SI3345895T1 (sl) | 2003-04-11 | 2020-03-31 | Ptc Therapeutics, Inc. | Spojina 1,2,4-oksadiazol benzojske kisline in njena uporaba za supresijo nesmiselne in zdravljenje bolezni |
| US20060252741A1 (en) * | 2003-05-15 | 2006-11-09 | Colandrea Vincent J | 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists |
| CN1859908A (zh) * | 2003-10-01 | 2006-11-08 | 默克公司 | 作为s1p受体激动剂的3,5－芳基、杂芳基或环烷基取代的－1,2,4－噁二唑类化合物 |
| CA2547198A1 (en) * | 2003-12-17 | 2005-06-30 | Merck & Co., Inc. | (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists |
| JPWO2005108370A1 (ja) * | 2004-04-16 | 2008-03-21 | 味の素株式会社 | ベンゼン化合物 |
| MXPA06013912A (es) | 2004-05-29 | 2007-07-18 | 7Tm Pharma As | Ligandos del receptor de crth2 para usos medicinales. |
| WO2006047195A2 (en) * | 2004-10-22 | 2006-05-04 | Merck & Co., Inc. | 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists |
| CA2610310A1 (en) * | 2005-06-08 | 2006-12-14 | Novartis Ag | Polycyclic oxadiazoles or isoxazoles and their use as s1p receptor ligands |
| WO2007043400A1 (ja) * | 2005-10-07 | 2007-04-19 | Kissei Pharmaceutical Co., Ltd. | 含窒素芳香族複素環化合物およびそれを含有する医薬組成物 |
| TWI404706B (zh) * | 2006-01-11 | 2013-08-11 | Actelion Pharmaceuticals Ltd | 新穎噻吩衍生物 |
| JP2009269819A (ja) | 2006-08-25 | 2009-11-19 | Asahi Kasei Pharma Kk | アミン化合物 |
| EP2081916A1 (en) | 2006-09-29 | 2009-07-29 | Novartis AG | Oxadiazole derivatives with anti-inflammatory and immunosuppressive properties |
| NZ577111A (en) | 2006-12-15 | 2012-05-25 | Abbott Lab | Novel oxadiazole compounds |
| EP2014653A1 (en) | 2007-06-15 | 2009-01-14 | Bioprojet | Novel dicarboxylic acid derivatives as S1P1 receptor agonists |
| EA201070422A1 (ru) * | 2007-10-04 | 2010-12-30 | Мерк Сероно С.А. | Производные оксадиазола |
| CN104478821B (zh) * | 2007-10-04 | 2016-09-28 | 默克雪兰诺有限公司 | 噁二唑二芳基化合物 |
-
2008
- 2008-10-01 CN CN201410603560.6A patent/CN104478821B/zh not_active Expired - Fee Related
- 2008-10-01 EP EP08804975.4A patent/EP2193126B1/en active Active
- 2008-10-01 AU AU2008306886A patent/AU2008306886B2/en not_active Ceased
- 2008-10-01 BR BRPI0817597 patent/BRPI0817597A2/pt not_active IP Right Cessation
- 2008-10-01 CA CA2696829A patent/CA2696829C/en not_active Expired - Fee Related
- 2008-10-01 EA EA201070423A patent/EA201070423A1/ru unknown
- 2008-10-01 MX MX2010003614A patent/MX2010003614A/es not_active Application Discontinuation
- 2008-10-01 JP JP2010527450A patent/JP5727223B2/ja not_active Expired - Fee Related
- 2008-10-01 ES ES08804975.4T patent/ES2547877T3/es active Active
- 2008-10-01 US US12/675,254 patent/US8404676B2/en active Active
- 2008-10-01 CN CN200880110507.5A patent/CN101815707B/zh not_active Expired - Fee Related
- 2008-10-01 WO PCT/EP2008/063185 patent/WO2009043890A1/en active Application Filing
- 2008-10-01 KR KR1020107009974A patent/KR20100083814A/ko not_active Application Discontinuation
- 2008-10-03 AR ARP080104332A patent/AR068730A1/es not_active Application Discontinuation
-
2010
- 2010-02-19 ZA ZA2010/01217A patent/ZA201001217B/en unknown
- 2010-03-16 IL IL204520A patent/IL204520A/en not_active IP Right Cessation
-
2012
- 2012-12-12 US US13/711,934 patent/US8889668B2/en not_active Expired - Fee Related
-
2014
- 2014-09-26 JP JP2014197234A patent/JP2015025001A/ja not_active Withdrawn
-
2016
- 2016-05-19 JP JP2016100693A patent/JP6224771B2/ja not_active Expired - Fee Related
